2024年医药研发年度回顾(英文)-202404-citeline-65页

WhitePaperPharmaR&DAnnualReview2024Lookbackatkeypipelinetrendsfromthelast12monthssoyoucanforecastsuccessin2024ContentsWelcome03Introduction:TotalPipelineSize05PleasantoutlookforpharmaasthingscontinuetoheatupDevelopingSystems:The2024PipelinebyPhase08ClinicaldevelopmentadvancesstillfaceastiffheadwindTopCompanies11Someenjoyamomentinthesun,butforothersthefuturelooksmorehazyTherapiesandDiseases19CancerstilltakingR&DbystormRegionalVariations31WheretheoutlookseemstobebrightestMechanismsandTargets54Immuno-oncologymakeshaywhilethesunshinesTypesofPipelineDrugs59Isthecontinuedmoveintobiotechstartingtomeetafrostyreception?What’stheForecastforPharma?62PlentyofraysofsunshineshouldholdoffanystormcloudsonthehorizonAbouttheAuthor65WelcomeWelcometoPharmaprojects’2024reviewoftrendsinpharmaceuticalR&DWelcometoPharmaprojects’2024reviewSinceourearlycave-dwellingdays,theactivitiesoftrendsinpharmaceuticalR&D.Foroverofhumanshavebeensomewhatgoverned30yearsnow,I’vebeentakinganannualbythevagariesoftheweather.WeneededtolookattheevolutionofpharmaR&D,andinknowwhenconditionswerebestforhunting,thisarticleI’lltakethetemperatureoftheandwhetherourcropswouldflourishorfail.Theindustryatthestartof2024.We’llassessearliestattemptstopredicttheweatherwereindustrytrendsbyexaminingthepipelinebylargelyunscientificandbasedonprophecy,company,therapeu...